Regular monitoring with imaging scans helps guide treatment length. Like all cancer therapies, Enhertu comes with potential side effects. However, its targeted nature means many patients ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Your doctor will test your cancer before you start treatment to determine whether Enhertu may be a good option for you. Enhertu is used to treat the following kinds of cancer in adults ...

Grade 3 or higher treatment related adverse events (TEAEs) occurred in 54.9% of patients in the ENHERTU plus pertuzumab arm and 52.4% of patients in the THP arm. The most common grade 3 or higher ...

Last week Australia announced that HER2-low metastatic patients could get Enhertu under a scheme that means that eligible patients would only pay a maximum of AU$31.60 (£16) per treatment or just ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

This is a significant milestone for patients and sets the foundation for ENHERTU in combination with pertuzumab as an important treatment option in the first-line HER2-positive setting." ...

The safety profile of ENHERTU in DESTINY-Gastric04 was consistent with previous gastric cancer clinical trials with no new safety concerns identified. The most common grade 3 or higher treatment ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

These results are important because many patients with metastatic breast cancer do not live long enough to receive a second line of treatment. Enhertu is an antibody drug conjugate (ADC ...